Trade Name(s)

  • Jetrea

Ther. Class.
ocular agents

Pharm. Class.


Symptomatic treatment of vitreomacular adhesion (VMA).


A proteolytic enzyme that dissolves the protein matrix present in vitreomacular adhesions.

Therapeutic Effect(s):

Dissolution of vitreomacular adhesion with improved vision.


Absorption: Minimal absorption

Distribution: Action is primarily local

Metabolism and Excretion: Rapidly degraded following administration

Half-life: Unknown.


Intravitrealwithin 1 wk3 wk6 mos or more


Contraindicated in:

  • None noted.

Use Cautiously in:

  • Lactation: Effects are not know, use caution;
  • OB:  Use during pregnancy only if clearly needed;
  • Pedi:  Safety and effectiveness not established.

Adverse Reactions/Side Effects

May be due to procedure

EENT: blurred vision, conjunctival hemorrhage, ↓ visual acuity, eye pain, macular hole, vitreous floaters, retinal edema, anterior chamber cell, cataract, conjunctival hyperemia, dry eye, dyschromatopsia (yellow vision), ↑ intraocular pressure, intraocular inflammation/infection, intraocular hemorrhage, iritis, lens subluxation, macular edema, metamorphopsia (distorted vision), photophobia, photopsia (perceived light flashes), retinal degeneration, retinal detachment, vitreous detachment

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



None noted.


Intravitreal (Adults): 0.125 mg injected as a single dose.


Solution for intravitreal injection: 0.375 mg/0.3 mL


  • Monitor for elevation in intraocular pressure following injection.
  • Monitor visual acuity periodically following injection; may lead to decrease in vision.

Potential Diagnoses


  • Ocriplasmin must be administered by a qualified physician.
  • Intravitreal Remove vial from freezer and allow to thaw for few min at room temperature. Solution is clear and colorless without particles; do not administer solutions that are discolored or contain particulate matter. Withdraw all solution from vial with a 19 gauge needle. Replace needle with 30 gauge needle and expel excess air and solution to 0.1 mL. Discard unused solution. Administer adequate anesthesia and a broad spectrum antibiotic as per protocol. Intravitreal injection is done via aseptic technique. Repeat administration in same eye is not recommended.
    • Wait 7 days before treating other eye if necessary.

Patient/Family Teaching

  • Explain procedure for intravitreal injection to patient.
  • Advise patient to notify health care professional immediately if signs and symptoms of intraocular inflammation/infection (eye redness, sensitivity to light, eye pain, change in vision) occurs.
  • May cause visual changes. Advise patient to avoid driving and other activities requiring good vision until response to medication is known.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Improved vision in patients with vitreomacular adhesions.

ocriplasmin is a sample topic from the Davis's Drug Guide.

To view other topics, please or .

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. .